Intervacc is trading 7.22% lower at $0.90, with the decline most consistent with broader biotech weakness and risk-off sentiment tied to rising oil prices, Treasury yields, inflation concerns and tightening expectations. - Shares fell from SEK 0.97 at the September 23 close; the move was substantially sharper than recent daily declines. - No September 24 company-specific announcement was identified. The latest update, announced September 15, concerned an October 1 healthcare conference; available evidence indicates no new Intervacc-specific catalyst.